drugset
Drugs / mesenchymal stem cells derived from bone marrow
last change Mar 2021 re-read 3 minutes ago

mesenchymal stem cells derived from bone marrow

also known as BM-MSCs

Cell therapy

Developed for
recessive dystrophic epidermolysis bullosa
Investigated by
CIBER Enfermedades raras · DEBRA · Instituto de Investigación Hospital Universitario La Paz · Instituto de Salud Carlos III · St John's Institute of Dermatology Kings College London · Universidad Carlos III Madrid (TERMeG)

Trials 1

today NCT04153630 · Ph 1/2
201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04153630 May 2018 → Mar 2021 recessive dystrophic epidermolysis bullosa Instituto de Investigación Hospital Universitario La Paz Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as mesenchymal stem cells derived from bone marrow ClinicalTrials.gov intervention name — accepted as the source's own label NCT04153630 ↗
Known as BM-MSCs “mesenchymal stem cells derived from bone marrow (BM-MSCs)” NCT04153630 ↗
Modality Cell therapy “Study drug: Allogenic mesenchymal cells (haploidentical) derived from bone marrow and expanded.” NCT04153630 ↗
Route Intravenous “administered by intravenous injection” NCT04153630 ↗